Position in ALKS
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$2,886,861
New position
Shares Held
81,642
first reported quarter
Ownership
0.049%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Vanguard Global Advisers, LLC holds $202,358,035 across 46 Drug Manufacturers - Specialty & Generic names. ALKS ranks #8 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
926,239 | $109,490,712 | |
| 2 | VTRS |
Viatris Inc
|
2,691,561 | $36,362,989 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
19,493 | $11,558,959 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
227,786 | $5,450,918 | |
| 5 | NBIX |
Neurocrine Biosciences Inc
|
40,647 | $5,354,835 | |
| 6 | BHC |
Bausch Health Companies Inc.
|
795,836 | $4,297,514 | |
| 7 | LNTH |
Lantheus Holdings, Inc.
|
41,134 | $3,120,013 | |
| 8 | ALKS |
Alkermes plc.
This page
|
81,642 | $2,886,861 |
All Filings in ALKS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,886,861 | 81,642 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||